Complete financial analysis of Pulse Biosciences, Inc. (PLSE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pulse Biosciences, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- China Shineway Pharmaceutical Group Limited (CSWYY) Income Statement Analysis – Financial Results
- Team17 Group plc (TSVNF) Income Statement Analysis – Financial Results
- T4F Entretenimento S.A. (SHOW3.SA) Income Statement Analysis – Financial Results
- Sono Group N.V. (SEV) Income Statement Analysis – Financial Results
- Control Print Limited (CONTROLPR.NS) Income Statement Analysis – Financial Results
Pulse Biosciences, Inc. (PLSE)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
Website: https://www.pulsebiosciences.com
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 700.00K | 1.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.21M | 11.94M | 1.97M | 665.00K | 666.00K | 665.00K | 665.00K | 665.00K | 0.00 | 0.00 |
| Gross Profit | -1.21M | -11.24M | -550.00K | -665.00K | -666.00K | -665.00K | -665.00K | -665.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | -1,606.29% | -38.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 27.80M | 20.84M | 28.64M | 26.44M | 24.96M | 17.25M | 9.65M | 5.99M | 2.58M | 44.57K |
| General & Administrative | 15.78M | 13.96M | 19.07M | 22.86M | 22.33M | 20.05M | 15.50M | 2.93M | 1.22M | 73.71K |
| Selling & Marketing | 0.00 | 12.02M | 14.75M | 7.26M | 5.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.78M | 25.97M | 33.82M | 22.86M | 22.33M | 20.05M | 15.50M | 2.93M | 1.22M | 73.71K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 665.00K | 666.00K | -28.00K | 665.00K | 665.00K | 665.39K | 0.00 |
| Operating Expenses | 43.57M | 46.81M | 62.46M | 49.97M | 47.95M | 37.96M | 25.81M | 9.59M | 4.47M | 514.29K |
| Cost & Expenses | 43.57M | 58.76M | 64.43M | 49.97M | 47.95M | 37.96M | 25.81M | 9.59M | 4.47M | 514.29K |
| Interest Income | 0.00 | 263.00K | 646.00K | 114.00K | 983.00K | 446.00K | 247.00K | 68.00K | 0.00 | 0.00 |
| Interest Expense | 1.36M | 448.00K | 646.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.21M | 1.36M | 1.15M | 1.10M | 1.16M | 1.31M | 1.00M | 759.00K | 716.98K | 200.57K |
| EBITDA | -42.37M | -56.70M | -61.87M | -48.87M | -46.79M | -36.65M | -24.57M | -8.83M | -3.75M | -108.00K |
| EBITDA Ratio | 0.00% | -8,293.86% | -4,443.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -43.57M | -58.06M | -63.01M | -49.97M | -47.95M | -37.96M | -25.81M | -9.59M | -4.47M | -308.57K |
| Operating Income Ratio | 0.00% | -8,293.86% | -4,443.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.36M | -448.00K | -646.00K | 114.00K | 983.00K | 418.00K | 247.00K | 68.00K | 0.00 | -396.00K |
| Income Before Tax | -42.21M | -58.51M | -63.66M | -49.85M | -46.97M | -37.55M | -25.57M | -9.52M | -4.47M | -514.29K |
| Income Before Tax Ratio | 0.00% | -8,357.86% | -4,489.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 448.00K | -500.00K | -114.00K | -983.00K | -28.00K | -912.00K | -94.00K | -1.66M | 39.43K |
| Net Income | -42.21M | -58.95M | -63.16M | -49.74M | -45.99M | -37.55M | -25.57M | -9.52M | -2.81M | -474.86K |
| Net Income Ratio | 0.00% | -8,421.86% | -4,454.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.88 | -1.74 | -2.26 | -2.14 | -2.22 | -2.20 | -1.73 | -0.86 | -0.37 | -0.19 |
| EPS Diluted | -0.88 | -1.74 | -2.26 | -2.14 | -2.22 | -2.20 | -1.73 | -0.86 | -0.37 | -0.19 |
| Weighted Avg Shares Out | 48.04M | 33.94M | 27.96M | 23.25M | 20.75M | 17.08M | 14.75M | 11.01M | 7.57M | 2.51M |
| Weighted Avg Shares Out (Dil) | 48.04M | 33.94M | 27.96M | 23.25M | 20.75M | 17.08M | 14.75M | 11.01M | 7.57M | 2.51M |
Pulse Biosciences Enhances Executive Leadership Team
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology (“Pulse”), today announced enhancements to its executive leadership team to support its next pivotal phase of growth. Proven atrial...
Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript
Pulse Biosciences Inc (NASDAQ:PLSE ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Philip Taylor - Principal, Gilmartin Group LLC Kevin Danahy - President & CEO Michael Koffler - VP, Finance Mitchell Levinson - Chief...
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2024. Recent Business Highlights CellFX...
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse” or the “Company”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that the Company's Board of Directors has set the record date for the...
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7,...
Pulse Biosciences Inc (PLSE) Q4 2023 Earnings Call Transcript
Pulse Biosciences Inc (PLSE) Q4 2023 Earnings Call Transcript
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2023. Recent...
Pulse Biosciences Announces Plans to Initiate a Rights Offering
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering. The rights offering...
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2023 after market...
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its novel CellFX nsPFA Percutaneous Electrode...
Source: https://incomestatements.info
Category: Stock Reports